Search This Blog

Wednesday, April 21, 2021

Ocugen: COVID Vax Development Partner Bharat Has 2nd Interim Results

 

  • Primary efficacy in the second interim analysis demonstrates COVAXIN to be 78% effective after the second dose in preventing COVID-19 in those without prior infection

  • Demonstrates 70% efficacy against asymptomatic COVID-19 infections; indicates potential to significantly reduce virus transmission

  • COVAXIN has been administered to several million people in India and is playing a critical role in combating the pandemic

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.